SCHEDULE: Qiming Entities Update Zai Lab Stake to 4.4%

Qiming Corporate GP IV and affiliated entities disclose a 4.4% beneficial ownership in Zai Lab Limited as of December 31, 2025.

Summary

• Qiming Corporate GP IV, Ltd., Qiming Managing Directors Fund IV, L.P., Qiming GP IV, L.P., Qiming Venture Partners IV, L.P., and QM11 Limited collectively reported beneficial ownership of Zai Lab Limited.
• QM11 Limited, Qiming Corporate GP IV, Ltd., Qiming GP IV, L.P., and Qiming Venture Partners IV, L.P. each beneficially own 48,883,643 ordinary shares, representing 4.4% of the outstanding class.
• Qiming Managing Directors Fund IV, L.P. beneficially owns 1,496,235 shares, representing 0.1% of the outstanding class.
• The total beneficial ownership of 48,883,643 ordinary shares is comprised of 280,680 American Depository Shares (ADSs) and 46,076,843 ordinary shares.
• The percentage of ownership is calculated based on an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025.
• The filing explicitly states ownership of 5 percent or less of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, factual disclosure of beneficial ownership by Qiming entities in Zai Lab Limited, providing transparency without indicating significant positive or negative operational developments.

Positives

• The continued disclosure of a significant, albeit below 5%, stake by Qiming entities suggests ongoing investment interest in Zai Lab Limited.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that beneficial ownership disclosures like this Schedule 13G provide transparency into institutional investor positions, which can sometimes signal confidence or changes in investment strategy within the biotechnology or pharmaceutical sector where Zai Lab operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Zai Lab Limited, Qiming Corporate GP IV, Qiming Managing Directors Fund IV, Qiming GP IV, Qiming Venture Partners IV, QM11 Limited, beneficial ownership, Schedule 13G, ordinary shares, ADSs, investment, equity